Inflammatory signatures across four photon radiotherapy and proton radiotherapy: mechanisms, mitigation, and quality of life impact

Yuting Sheng , Daniel M. Han , Mark R. Wakefield , Yujiang Fang

Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002334

PDF (3139KB)
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) :1002334 DOI: 10.37349/etat.2025.1002334
Review
research-article
Inflammatory signatures across four photon radiotherapy and proton radiotherapy: mechanisms, mitigation, and quality of life impact
Author information +
History +
PDF (3139KB)

Abstract

Cancer is the second leading cause of death globally and in the United States, second only to cardiovascular disease. Unlike many cardiovascular conditions, cancer is often less preventable, manageable, and curable-even with ongoing technological advancements in medicine. The adverse effects of cancer treatments on cancer patients remain profound due to shared cellular characteristics between cancerous and normal cells; one of the primary adverse effects is treatment-induced inflammation. These inflammatory responses aim to eliminate cancerous cells but often damage normal tissues. Notably, inflammatory side effects vary considerably across the growing diversity of therapeutic approaches. This study reviewed studies between 2007 and 2024, comparing the inflammatory profiles associated with five major radiation therapies (RTs): Three-Dimensional Conformal Radiation Therapy (3D-CRT), Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT), Stereotactic Body Radiation Therapy (SBRT), and Proton Beam Therapy (PBT)-each characterized by distinct mechanistic and therapeutic features. In addition to each radiation modality eliciting distinct inflammatory responses, tissue-specific variability further complicates clinical outcomes. Accordingly, this review also undertakes a cross-tissue comparison of radiation-induced inflammation, with a focus on the gastrointestinal (GI) system, central nervous system (CNS), and skin. However, the variation in treatment modalities and organ-specific inflammatory biomarkers greatly hinders direct comparison across studies. Finally, this review highlights potential inflammatory mitigations, including ambroxol, that may be employed synergistically with RTs, minimizing side effects and enhancing patient outcomes. Taken together, while all modalities offer therapeutic value alongside certain limitations, proton-based therapy demonstrates the greatest potential for minimizing toxicity though its broader adoption remains limited by cost-effectiveness concerns.

Keywords

Radiation-induced inflammation / radiation therapy modalities / quality of life / proton therapy

Cite this article

Download citation ▾
Yuting Sheng, Daniel M. Han, Mark R. Wakefield, Yujiang Fang. Inflammatory signatures across four photon radiotherapy and proton radiotherapy: mechanisms, mitigation, and quality of life impact. Exploration of Targeted Anti-tumor Therapy, 2025, 6 (1) : 1002334 DOI:10.37349/etat.2025.1002334

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Beaulieu L, Rivard MJ. Brachytherapy evolution as seen today. Med Phys. 2023; 50: 21-6.

[2]

Winter RC, Amghar M, Wacker AS, Bakos G, Taş H, Roscher M, et al. Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy. Pharmaceuticals (Basel). 2024; 17: 1031.

[3]

Huang X, Chen Q, Ren Y, Zhu J, Xu L, Huang S, et al. Three-dimensional conformal radiation therapy with concurrent chemotherapy for stage III non-small cell lung cancer: protocol for a systematic review and meta-analysis. BMJ Open. 2024; 14: e090728.

[4]

Song CW, Glatstein E, Marks LB, Emami B, Grimm J, Sperduto PW, et al. Biological Principles of Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Radiation Surgery (SRS): Indirect Cell Death. Int J Radiat Oncol Biol Phys. 2021; 110: 21-34.

[5]

Rutkowski J, Nowicka Z, Ślebioda T, Sobocki B, Tomasik B, Kmieć Z, et al. Changes in Systemic Immune Response and Its Dosimetric Correlates in Patients with Non-Small-Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2024; 120: e392-3.

[6]

Ashrafizadeh M, Farhood B, Musa AE, Taeb S, Najafi M. Damage-associated molecular patterns in tumor radiotherapy. Int Immunopharmacol. 2020; 86: 106761.

[7]

Lee MS, Kim Y. Pattern-recognition receptor signaling initiated from extracellular, membrane, and cytoplasmic space. Mol Cells. 2007; 23: 1-10.

[8]

Wang Y, Xiang Y, Xin VW, Wang X, Peng X, Liu X, et al. Dendritic cell biology and its role in tumor immunotherapy. J Hematol Oncol. 2020; 13: 107.

[9]

Nelson BE, Adashek JJ, Lin SH, Subbiah V. The abscopal effect in patients with cancer receiving immunotherapy. Med. 2023; 4: 233-44.

[10]

Sanmamed N, Alcantara P, Gómez S, Bustos A, Cerezo E, Gaztañaga M, et al. Low-dose Radiation Therapy in the Management of COVID-19 Pneumonia (LOWRAD-Cov19). Final results of a prospective phase I-II trial. Radiother Oncol. 2022; 171: 25-9.

[11]

Soerjomataram I, Bray F. Planning for tomorrow: global cancer incidence and the role of prevention 2020-2070. Nat Rev Clin Oncol. 2021; 18: 663-72.

[12]

Dar TB, Nguyen AT, Stevens S, Viramontes J, Henson R, Jang JK, et al. Reshaping Macrophage Polarization Potential Enhances Antitumor Immune Response to Radiation Therapy. Int J Radiat Oncol Biol Phys. 2023; 117: e225-6.

[13]

Cytlak UM, Dyer DP, Honeychurch J, Williams KJ, Travis MA, Illidge TM. Immunomodulation by radiotherapy in tumour control and normal tissue toxicity. Nat Rev Immunol. 2022; 22: 124-38.

[14]

Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021; 6: 263.

[15]

Bower JE, Ganz PA, Tao ML, Hu W, Belin TR, Sepah S, et al. Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. Clin Cancer Res. 2009; 15: 5534-40.

[16]

Tanaka H, Nakabe C, Hironaka A, Ueda K, Karita M, Ono T, et al. Systemic inflammation biomarkers are prognostic factors in palliative radiation therapy for stage IV lung cancer. Int J Radiat Oncol Biol Phys. 2024; 120: e278.

[17]

Takaoka T, Shibamoto Y, Murai T, Kobayashi M, Sugie C, Manabe Y, et al. Helical tomotherapy for chemo-refractory multiple liver metastases. Cancer Med. 2019; 8: 7594-602.

[18]

Zhu M, Yang M, Zhang J, Yin Y, Fan X, Zhang Y, et al. Immunogenic Cell Death Induction by Ionizing Radiation. Front Immunol. 2021; 12: 705361.

[19]

Demaria O, Cornen S, Daëron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019; 574: 45-56. Erratum in: Nature. 2019;576:E3.

[20]

Wu CT, Chen MF, Chen WC, Hsieh CC. The role of IL-6 in the radiation response of prostate cancer. Radiat Oncol. 2013; 8: 159.

[21]

Culig Z, Puhr M. Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol. 2012; 360: 52-8.

[22]

Wen Y, Zhu Y, Zhang C, Yang X, Gao Y, Li M, et al. Chronic inflammation, cancer development and immunotherapy. Front Pharmacol. 2022; 13: 1040163.

[23]

Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019; 51: 27-41.

[24]

Browning L, Patel MR, Horvath EB, Tawara K, Jorcyk CL. IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis. Cancer Manag Res. 2018; 10: 6685-93.

[25]

Theoharides TC. Mast cells and pancreatic cancer. N Engl J Med. 2008; 358: 1860-1.

[26]

Zhang C, Liang Z, Ma S, Liu X. Radiotherapy and Cytokine Storm: Risk and Mechanism. Front Oncol. 2021; 11: 670464.

[27]

Schaue D, Micewicz ED, Ratikan JA, Xie MW, Cheng G, McBride WH. Radiation and inflammation. Semin Radiat Oncol. 2015; 25: 4-10.

[28]

Molla M, Panes J. Radiation-induced intestinal inflammation. World J Gastroenterol. 2007; 13: 3043-6.

[29]

Liu Q, Huang Y, Duan M, Yang Q, Ren B, Tang F. Microglia as Therapeutic Target for Radiation-Induced Brain Injury. Int J Mol Sci. 2022; 23: 8286.

[30]

Haruwaka K, Ikegami A, Tachibana Y, Ohno N, Konishi H, Hashimoto A, et al. Dual microglia effects on blood brain barrier permeability induced by systemic inflammation. Nat Commun. 2019; 10: 5816.

[31]

Pereira Dias G, Hollywood R, Bevilaqua MC, da Luz AC, Hindges R, Nardi AE, et al. Consequences of cancer treatments on adult hippocampal neurogenesis: implications for cognitive function and depressive symptoms. Neuro Oncol. 2014; 16: 476-92.

[32]

Pazzaglia S, Briganti G, Mancuso M, Saran A. Neurocognitive Decline Following Radiotherapy: Mechanisms and Therapeutic Implications. Cancers (Basel). 2020; 12: 146.

[33]

Wei J, Meng L, Hou X, Qu C, Wang B, Xin Y, et al. Radiation-induced skin reactions: mechanism and treatment. Cancer Manag Res. 2018; 11: 167-77.

[34]

Rübe CE, Freyter BM, Tewary G, Roemer K, Hecht M, Rübe C. Radiation Dermatitis: Radiation-Induced Effects on the Structural and Immunological Barrier Function of the Epidermis. Int J Mol Sci. 2024; 25: 3320.

[35]

Liao W, Hei TK, Cheng SK. Radiation-Induced Dermatitis is Mediated by IL17-Expressing γδ T Cells. Radiat Res. 2017; 187: 454-64.

[36]

Ni J, Guo T, Zhou Y, Jiang S, Zhang L, Zhu Z. STING signaling activation modulates macrophage polarization via CCL2 in radiation-induced lung injury. J Transl Med. 2023; 21: 590.

[37]

Van’t Land FR, Aziz MH, Michiels N, Mieog JSD, Bonsing BA, Luelmo SAC, et al. Increasing Systemic Immune-inflammation Index During Treatment in Patients With Advanced Pancreatic Cancer is Associated With Poor Survival: A Retrospective, Multicenter, Cohort Study. Ann Surg. 2023; 278: 1018-23.

[38]

Li J, Liu M, Sun P, Zhao W, Song M, Liu Y. Three-Dimensional Conformal Radiotherapy Combined with Gemcitabine and Docetaxel in the Treatment of Advanced Bladder Cancer and Its Effects on Inflammatory Factors and Immune Function. J Oncol. 2022; 2022: 9347218.

[39]

Chun SG, Hu C, Choy H, Komaki RU, Timmerman RD, Schild SE, et al. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. J Clin Oncol. 2017; 35: 56-62.

[40]

Wang S, Tang W, Luo H, Peng H, Jin F, He H, et al. The Impact of Image Guided Radiation Therapy (IGRT) on Efficacy and Toxicity of Prostate Cancer: A Systematic Review and Meta-Analysis. Int J Radiat Oncol Biol Phys. 2022; 114: e562-3.

[41]

Li Y, Dykstra M, Best TD, Pursley J, Chopra N, Keane FK, et al. Differential inflammatory response dynamics in normal lung following stereotactic body radiation therapy with protons versus photons. Radiother Oncol. 2019; 136: 169-75.

[42]

Davuluri R, Jiang W, Fang P, Xu C, Komaki R, Gomez DR, et al. Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy. Int J Radiat Oncol Biol Phys. 2017; 99: 128-35.

[43]

Montay-Gruel P, Meziani L, Yakkala C, Vozenin M. Expanding the therapeutic index of radiation therapy by normal tissue protection. Br J Radiol. 2019; 92: 20180008.

[44]

Wang X, Wei L, Cramer JM, Leibowitz BJ, Judge C, Epperly M, et al. Pharmacologically blocking p53-dependent apoptosis protects intestinal stem cells and mice from radiation. Sci Rep. 2015; 5: 8566.

[45]

Mahmood J, Jelveh S, Calveley V, Zaidi A, Doctrow SR, Hill RP. Mitigation of lung injury after accidental exposure to radiation. Radiat Res. 2011; 176: 770-80.

[46]

Xia D, Xi L, Xv C, Mao W, Shen W, Shu Z, et al. The protective effects of ambroxol on radiation lung injury and influence on production of transforming growth factor beta1 and tumor necrosis factor alpha. Med Oncol. 2010; 27: 697-701.

[47]

Baumann BC, Mitra N, Harton JG, Xiao Y, Wojcieszynski AP, Gabriel PE, et al. Comparative Effectiveness of Proton vs Photon Therapy as Part of Concurrent Chemoradiotherapy for Locally Advanced Cancer. JAMA Oncol. 2020; 6: 237-46.

[48]

Brown PD, Chung C, Liu DD, McAvoy S, Grosshans D, Feghali KA, et al. A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma. Neuro Oncol. 2021; 23: 1337-47.

[49]

Lin SH, Hobbs BP, Verma V, Tidwell RS, Smith GL, Lei X, et al. Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol. 2020; 38: 1569-79.

[50]

de González AB, Gibson TM, Lee C, Albert PS, Griffin KT, Kitahara CM, et al. The Pediatric Proton and Photon Therapy Comparison Cohort: Study Design for a Multicenter Retrospective Cohort to Investigate Subsequent Cancers After pediatric Radiation Therapy. Adv Radiat Oncol. 2023; 8: 101273.

[51]

Byun HK, Han MC, Yang K, Kim JS, Yoo GS, Koom WS, et al. Physical and Biological Characteristics of Particle Therapy for Oncologists. Cancer Res Treat. 2021; 53: 611-20.

[52]

Keam S, MacKinnon KM, D’Alonzo RA, Gill S, Ebert MA, Nowak AK, et al. Effects of Photon Radiation on DNA Damage, Cell Proliferation, Cell Survival, and Apoptosis of Murine and Human Mesothelioma Cell Lines. Adv Radiat Oncol. 2022; 7: 101013.

[53]

Aldenhoven L, Ramaekers B, Degens J, Oberije C, van Loon J, Dingemans AC, et al. Cost-effectiveness of proton radiotherapy versus photon radiotherapy for non-small cell lung cancer patients: exploring the model-based approach. Radiother Oncol. 2023; 183: 109417.

[54]

Doyen J, Falk AT, Floquet V, Hérault J, Hannoun-Lévi J. Proton beams in cancer treatments: Clinical outcomes and dosimetric comparisons with photon therapy. Cancer Treat Rev. 2016; 43: 104-12.

[55]

Gupta A, Khan AJ, Goyal S, Millevoi R, Elsebai N, Jabbour SK, et al. Insurance Approval for Proton Beam Therapy and its Impact on Delays in Treatment. Int J Radiat Oncol Biol Phys. 2019; 104: 714-23.

[56]

LaRiviere MJ, Santos PMG, Hill-Kayser CE, Metz JM. Proton Therapy. Hematol Oncol Clin North Am. 2019; 33: 989-1009.

[57]

Mohan R. A Review of Proton Therapy - Current Status and Future Directions. Precis Radiat Oncol. 2022; 6: 164-76.

[58]

Feldman J, Pryanichnikov A, Achkienasi A, Polyansky I, Hillman Y, Raskin S, et al. Commissioning of a novel gantry-less proton therapy system. Front Oncol. 2024; 14: 1417393.

[59]

Mavragani IV, Nikitaki Z, Kalospyros SA, Georgakilas AG. Ionizing Radiation and Complex DNA Damage: From Prediction to Detection Challenges and Biological Significance. Cancers (Basel). 2019; 11: 1789.

[60]

Green LM, Murray DK, Bant AM, Kazarians G, Moyers MF, Nelson GA, et al. Response of thyroid follicular cells to gamma irradiation compared to proton irradiation. I. Initial characterization of DNA damage, micronucleus formation, apoptosis, cell survival, and cell cycle phase redistribution. Radiat Res. 2001; 155: 32-42.

[61]

MacDonald KM, Benguerfi S, Harding SM. Alerting the immune system to DNA damage: micronuclei as mediators. Essays Biochem. 2020; 64: 753-64.

[62]

Gajewski TF, Schreiber H, Fu Y. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013; 14: 1014-22.

[63]

Mirjolet C, Nicol A, Limagne E, Mura C, Richard C, Morgand V, et al. Impact of proton therapy on antitumor immune response. Sci Rep. 2021; 11: 13444.

[64]

Nantavithya C, Prayongrat A, Laohavinij W, Techavichit P, Srilanchakon K, Utoomprurkporn N, et al. Cost-Effectiveness of Proton Versus Photon Therapy for Medulloblastoma Using Updated Clinical Outcomes. Int J Part Ther. 2025; 17: 100754.

PDF (3139KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉